GLP-1 and Diabetes Management: How Ozempic Changes Blood Sugar Control

GLP-1 and Diabetes Management: How Ozempic Changes Blood Sugar Control

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

How GLP-1 Medications Regulate Blood Sugar

The Four Mechanisms

1. Glucose-dependent insulin secretion: GLP-1 binds to receptors on pancreatic beta cells, enhancing insulin release — but ONLY when blood glucose is elevated. When glucose normalizes, the insulin stimulation stops. This is why GLP-1 medications rarely cause hypoglycemia on their own.
2. Glucagon suppression: Glucagon (from alpha cells) tells the liver to release stored glucose. In type 2 diabetes, glucagon is inappropriately elevated. GLP-1 suppresses glucagon, reducing the liver's glucose output.
3. Delayed gastric emptying: Food reaches the small intestine more slowly → carbohydrates are absorbed gradually → post-meal blood sugar spikes are significantly blunted. This is one of the most impactful mechanisms for day-to-day blood sugar control.
4. Beta cell preservation: GLP-1 promotes beta cell survival and may even stimulate beta cell regeneration. This is potentially disease-modifying — not just symptom control, but actual preservation of the insulin-producing cells.

Clinical Results

• HbA1c reduction: Semaglutide 1mg weekly reduced HbA1c by 1.5-1.8% in the SUSTAIN trials
• Fasting glucose: Significant reductions in fasting blood glucose
• Post-meal glucose: Dramatic reduction in post-prandial glucose spikes (the most harmful pattern for vascular damage)
• Weight loss: 5-10% weight loss in diabetic patients, which independently improves insulin sensitivity
• Cardiovascular protection: SUSTAIN-6 showed 26% reduction in major cardiovascular events. SELECT showed cardiovascular benefit in non-diabetic obese patients as well.

GI Challenges for Diabetic Patients

Why GI Side Effects May Be Worse

• Diabetic gastroparesis: 20-50% of long-standing diabetics already have delayed gastric emptying from vagus nerve damage (autonomic neuropathy). Adding GLP-1 further slows an already slow stomach → severe nausea, early satiety, vomiting.
• Diabetic autonomic neuropathy: The enteric nervous system is affected by diabetes. Intestinal motility is already disrupted → GLP-1 adds another motility-altering factor.
• Medication interactions: Metformin causes GI side effects in ~30% of users. GLP-1 + metformin = additive GI effects. SGLT2 inhibitors may also contribute to GI symptoms.

Management Strategies

1. Slower titration: If you have known gastroparesis, discuss extended titration schedules with your prescriber.
2. Smaller, more frequent meals: 5-6 mini-meals instead of 3 large ones. Reduces the volume sitting in a slowly emptying stomach.
3. Low-fiber, low-fat meals during titration: Fiber and fat slow gastric emptying further. During the adjustment period, eat simpler, more digestible foods.
4. Time metformin with meals: If taking both, ensure metformin is taken with food to reduce additive nausea.
5. Monitor blood sugar closely during titration: As GLP-1 takes effect, other diabetes medications may need dose reduction to prevent hypoglycemia.